Citation Impact
Citing Papers
Diagnosis, management, and treatment of hepatitis C†
2004
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Mortality in the Highly Active Antiretroviral Therapy Era
2006
Study of hepatitis C virus entry in genetically humanized mice
2012 StandoutNobel
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Hepatitis C virus infection
2005
Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV‐Infected Patients
2007
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
2014
Hepatitis C Virus Infection in African Americans
2005
The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture
2005
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells
2010 StandoutNobel
Hepatitis C Virus in the HIV-Infected Patient
2006
Molecular mechanism and function of CD40/CD40L engagement in the immune system
2009
COVID-19: A promising cure for the global panic
2020 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Acute hepatitis C: Current status and remaining challenges
2008
Treating viral hepatitis C: efficacy, side effects, and complications
2006
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals
2014
Successes and Challenges on the Road to Cure Hepatitis C
2015
PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
2006
Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV‐infected persons
2006
Arylacetamide deacetylase: A novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production
2013 StandoutNobel
American Gastroenterological Association Technical Review on the Management of Hepatitis C
2006
Designing hydrogels for controlled drug delivery
2016 Standout
Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection
2008
The Beta Cell in Type 2 Diabetes
2019
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus†
2009
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults
2007
Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN α2b plus ribavirin in HIV/HCV co-infected patients
2007
Immunoisolating semi-permeable membranes for cell encapsulation: Focus on hydrogels
2011
FIB-4
2007 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Regulation of type I interferon responses
2013 Standout
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
2006 Standout
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Long-term Functioning of Allogeneic Islets in Subcutaneous Tissue Pretreated With a Novel Cyclic Peptide Without Immunosuppressive Medication
2017 StandoutNobel
Therapy of Hepatitis C: From Empiricism to Eradication
2006
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
2011
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Mesenchymal Stem Cell and Islet Co-Transplantation Promotes Graft Revascularization and Function
2010
Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2004
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Replication of hepatitis C virus
2007 StandoutNobel
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
2009
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir
2008
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Follicular Helper CD4 T Cells (TFH)
2011 Standout
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
2006 Standout
Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B
2014 StandoutNobel
Pathophysiology of Type 2 Diabetes Mellitus
2020 Standout
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Interferon signatures in immune disorders and disease
2012
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice
2021 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain
2006
Hepatitis C in Children
2006
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
2006 Standout
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design
2013 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of George Harb being referenced
Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
2004
Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
2018
Prolonged Survival of Microencapsulated Neonatal Porcine Islets in Mice Treated with a Combination of Anti-CD154 and Anti-LFA-1 Monoclonal Antibodies
2005
Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia
2009
Survival of Microencapsulated Islets at 400 Days Posttransplantation in the Omental Pouch of NOD Mice
2006
The safety, efficacy and pharmacokinetics of peginterferon Alfa-2a (40KD) in children with chronic hepatitis C
2003
Survey of the Human Pancreatic β-Cell G1/S Proteome Reveals a Potential Therapeutic Role for Cdk-6 and Cyclin D1 in Enhancing Human β-Cell Replication and Function In Vivo
2009